The UK recently unveiled a life sciences sector plan that has sparked mixed reactions within the pharmaceutical industry. While the proposal to enhance research and development was well-received, concerns were raised regarding the competitiveness of firms without a resolution on drug pricing. This initiative is part of the government’s broader industrial strategy, which includes eight priority sectors, with life sciences being a key focus.
Despite delays in finalizing sector-specific details due to disagreements between the pharma industry and the government, the plan aims to address challenges in attracting investments and streamlining the regulation of medicines for the National Health Service. Industry leaders have expressed reservations about the UK’s pricing regime, emphasizing the need for a balance between cost containment and fostering innovation in the healthcare sector.
Read more on gcn.com